Description
CDC-Enhanced Panitumumab is a Fc-modified anti-EGFR therapeutic biobetter antibody. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Panitumumab, Panitumumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Colorectal cancers, metastatic (EGFR positive)
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
Epidermal Growth Factor Receptor
Background
The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. [provided by RefSeq, Jun 2016]
Alternative Names
Cetuximab; erbitux; 205923-56-4; Epidermal growth factor receptor inhibitor; EGFR inhibitor; DB00002EGFR; epidermal growth factor receptor; epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog), ERBB; ERBB1;
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Human IgG2, κ
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human EGFR. Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).
Indication
Colorectal cancers, metastatic (EGFR positive)
